-
Stocks Battle Back 01-25-2011
Friday, January 28, 2011 - 7:24pm | 929Cusick's Corner Global Growth, Inflation and the Confidence of the Consumer all came into play this afternoon, and in the end the market bounced back as it has all to often the last three months. This further highlights that 2011 is going to be a market timer type of market. If you are not a...
-
optionsXpress Will Ring Opening Bell at NASDAQ 01-25-2011
Friday, January 28, 2011 - 7:19pm | 928Cusick's Corner I just landed in NYC for optionsXpress' 10th Anniversary and tomorrow's Bell Ringing Ceremony with customers at the NASDAQ Market Site. The market started off weak, news that the UK's economy contracted in the 4th Quarter also revived some concerns over Spanish Banks. The Dollar is...
-
Busy Earnings Week Ahead - Earnings Preview
Friday, January 28, 2011 - 5:31pm | 4956Earnings Preview 1/28/11 Next week the fourth quarter earnings season is in full swing. A total of 561 firms are due to report, including 106 S&P 500 firms. So far the earnings season seems to be going well. The firms reporting this week include several icons of U.S. business, including: Aflac...
-
Johnson & Johnson Acquisition of Crucell Receives Approval from EC
Friday, January 28, 2011 - 2:59pm | 40Johnson & Johnson (NYSE: JNJ) and Crucell (Nasdaq: CRXL) today announced that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of Crucell.
-
AstraZeneca Revenues Disappoint - Analyst Blog
Friday, January 28, 2011 - 2:39pm | 945AstraZeneca plc's (AZN) fourth-quarter earnings came in at $1.39 per American Depositary Share (ADS), six cents above the Zacks Consensus Estimate but 2% below the year-ago figure of $1.42. Full year earnings came in at $6.71, well ahead of the Zacks Consensus Estimate of $6.62 and 6% above the...
-
SRDX Beats on EPS, Sales Slip - Analyst Blog
Friday, January 28, 2011 - 2:31pm | 726SurModics Inc.'s (SRDX) first quarter fiscal 2011 earnings (excluding special items) of $0.05 per share was well ahead of the break even earnings suggested by the Zacks Consensus Estimate. However, earnings fell short of the year-ago earnings of $0.11. The weak year-over-year performance in the...
-
AstraZeneca Revenues Disappoint - Analyst Blog
Friday, January 28, 2011 - 2:12pm | 945AstraZeneca plc's (AZN) fourth-quarter earnings came in at $1.39 per American Depositary Share (ADS), six cents above the Zacks Consensus Estimate but 2% below the year-ago figure of $1.42. Full year earnings came in at $6.71, well ahead of the Zacks Consensus Estimate of $6.62 and 6% above the...
-
SRDX Beats on EPS, Sales Slip - Analyst Blog
Friday, January 28, 2011 - 2:00pm | 726SurModics Inc.'s (SRDX) first quarter fiscal 2011 earnings (excluding special items) of $0.05 per share was well ahead of the break even earnings suggested by the Zacks Consensus Estimate. However, earnings fell short of the year-ago earnings of $0.11. The weak year-over-year performance in the...
-
Positive Phase IV Data on Nuvigil - Analyst Blog
Friday, January 28, 2011 - 1:01pm | 612Cephalon, Inc. (CEPH) recently presented positive data on Nuvigil from a six-week, multi-center, double-blind phase IV study that was conducted in patients suffering from excessive sleepiness associated with shift work disorder, especially during the end of their night shifts. Results from the...
-
Positive Phase IV Data on Nuvigil - Analyst Blog
Friday, January 28, 2011 - 12:30pm | 612Cephalon, Inc. (CEPH) recently presented positive data on Nuvigil from a six-week, multi-center, double-blind phase IV study that was conducted in patients suffering from excessive sleepiness associated with shift work disorder, especially during the end of their night shifts. Results from the...
-
Puts Purchased on Salix Pharmaceuticals (SLXP)
Friday, January 28, 2011 - 12:15pm | 125Shares of Salix Pharmaceuticals (NASDAQ: SLXP) are lower on the session by 2.09%, currently trading at $40.84. The stock has been moving largely lower over the past month and is currently consolidating between the 50-day and 200-day moving averages. Options traders are buying puts on the name...
-
Vaccines Pull Down NVS Q4 Earnings - Analyst Blog
Friday, January 28, 2011 - 11:31am | 1010Novartis (NVS) reported earnings per share of $1.14 for the fourth quarter of 2010, much below the Zacks Consensus Estimate of $1.21 and the year-earlier earnings of $1.26 per share. The substantial drop from the base period was due to robust profits booked in 2009 from windfall sales of H1N1 flu...
-
Vaccines Pull Down NVS Q4 Earnings - Analyst Blog
Friday, January 28, 2011 - 11:15am | 1010Novartis (NVS) reported earnings per share of $1.14 for the fourth quarter of 2010, much below the Zacks Consensus Estimate of $1.21 and the year-earlier earnings of $1.26 per share. The substantial drop from the base period was due to robust profits booked in 2009 from windfall sales of H1N1 flu...
-
Company News for January 28, 2011 - Corporate Summary
Friday, January 28, 2011 - 11:01am | 788• Microsoft (NASDAQ:MSFT) reported Q2 EPS of $0.77, above the Zacks Consensus Estimate of $0.55 per share. Revenues for the quarter were $19.95 billion, well above the Zacks Consensus Estimate of $16.073 billion • Amazon.com (NASDAQ:AMZN) reported Q4 EPS of $0.91, ahead of the Zacks Consensus...
-
Hapoalim Securities Reiterates Sell Rating on Bristol-Myers Squibb (BMY)
Friday, January 28, 2011 - 10:54am | 159Hapoalim Securities is out with a research report this morning, where it reiterates its Hold rating on First Republic Bank (NYSE: BMY); it has a $31.00 price target on the stock. The HS analysts cited the company's earnings release, which showed in-line continuing EPS of $0.47 on lower revenues and...